Loading...

COVID‑19 Alert: Stay home if you feel unwell. If you have a fever, cough and difficulty breathing, seek medical attention. Follow the directions of your local health authority. Source WHO

We have a lockdown, "Working from HOME" Please reach out for any queries at: help@alliedmarketresearch.com & Int'l : +1-503-894-6022, (UK) : +44-845-528-1300

New

Meningococcal Vaccine Market by Serogroup (MenACWY, MenB/BC, MenC, MenAC, and MenA), Vaccine Type (Conjugate, Polysaccharide, and Subcapsular), and End User (Pediatric, Adults, and Travelers): Global Opportunity Analysis and Industry Forecast, 2018–2026

A00240
Pages: 197
Apr 2020 | 5160 Views
 
Author(s) : Sahil, Apoorva
Tables: 105
Charts: 28
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Meningococcal Vaccine Market

Request Now !

The global meningococcal vaccine market size was valued at $1,935.5 million in 2018, and is projected to reach $4,192.6 million by 2026, registering a CAGR of 9.5% from 2019 to 2026. Invasive meningococcal disease (IMD) is a bacterial infection caused by a gram-negative coccus, Neisseria meningitidis, which includes spectrum of infections including meningitis, bacteremia (meningococcemia), and bacteremia pneumonia. Although meningococcal disease is rare but is associated with high fatality of up to 50% if left untreated and often results in serious complications there  after. Meningococcal meningitis results in infection of the lining of the brain and spinal cord and also has a potential to cause large epidemics as well as endemics. The disease is generally transmitted through direct contact with droplets of respiratory or throat secretions from patients or asymptomatic carriers. Various serotypes of N. meningitidis are included in 12 serogroups of which only 5 serogroups including A, B, C, W, and Y are responsible for the majority of disease worldwide. However, circulation of these serogroups is highly unpredictable and varies over time across age groups and geographies. Vaccines for each of these serogroups are available in the market. 

The global meningococcal vaccine market is expected to experience significant market growth during the forecast period as there has been an increase in adoption in several countries across the globe in their national immunization programs. In addition, surge in meningococcal outbreaks in several countries has led to upsurge in demand for meningococcal vaccines, which further facilitate the growth of the market. However, stringent government regulations for the approval of new vaccines and recall of several products due to contamination are expected to impede the market growth. On the contrary, increase in R&D for meningococcal vaccines and global increase in healthcare spending provide significant growth opportunities for the meningococcal vaccine market. 

Meningococcal-Market-2019-2026

Get more information on this report : Request Sample Pages

Global Meningococcal Vaccine Market Segmentation

The Meningococcal Vaccine Market is segmented on the basis of serogroup, vaccine type, end user, and region. The serogroups covered in the study include MenACWY, MenB/BC, MenC, MenAC, and MenA. Depending on vaccine type, the market is classified into conjugate, polysaccharide, and subcapsular. According to end user, the market is segmented into pediatric, adults, and travelers .Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Meningococcal Vaccine Market
By Vaccine Serotype

Your browser does not support the canvas element.

MenACWY Vaccines segment holds a dominant position in 2019 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Vaccine serotype segment review

By vaccine serotype, the MenACWY vaccine and MenC vaccine segments collectively accounted for around 74.3% market share in 2018, with the former constituting around 46.2% share, and are expected to experience rapid growth during the forecast period as these vaccines exhibit increase in adoption in several countries across the globe in their national immunization programs. Moreover, meningococcal out breaks in several countries has led to upsurge in demand for meningococcal vaccines, which further swelled up the growth of the market is another reason that boosts the growth of the meningococcal vaccine market. However, MenA vaccine is anticipated to be the fastest growing segment and is estimated to garner significant share by 2026, registering a CAGR of 13.5%.

Meningococcal Vaccine Market
By Vaccine Type

Your browser does not support the canvas element.

Conjugate segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Vaccine type segment review

By vaccine type, the conjugate vaccine segment accounted for the major market share in 2018, and is expected to experience rapid growth during the forecast period, owing to its key advantages such as longer lasting immunity and its ability to induce herd immunity. Moreover, various key players have several meningococcal conjugate vaccine products in their pipeline that provides significant opportunities for the growth of the conjugate vaccine market. In addition, conjugate vaccine is anticipated to be the fastest growing segment and is estimated to register a CAGR of 10.2%.

Meningococcal Vaccine Market
By End User

Your browser does not support the canvas element.

Pediatric segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

End user segment review

By end user, the pediatric and adult segments collectively accounted for around 95.2% market share in 2018, with the former constituting around 62.35% share and are expected to experience rapid growth during the forecast period due to increase in adoption in several countries across the globe in their national immunization programs. In addition, the pediatric segment is anticipated to be the fastest growing, registering a CAGR of 10.0%.

North America and Europe are the most lucrative markets due to increase in awareness for meningococcal diseases, ease of product availability, and surge in outbreaks for meningococcal diseases. The North America for largest market share for meningococcal vaccine market revenue in 2018. In addition, it is estimated to garner significant share by 2026 at an estimated CAGR of 9.4%. The Asia-Pacific Meningococcal Vaccine Market is estimated to account for the fastest growing sub-segment globally. The steady meningococcal vaccine market growth in this region can be primarily attributed to the presence of large population, improving access to healthcare systems, and increase in awareness for meningococcal diseases.

Meningococcal Vaccine Market
By Region

2026
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 14.7% during 2019-2026.

Get more information on this report : Request Sample Pages

Comprehensive competitive analysis and profiles of major meningococcal vaccine market players such as Bio-Manguinhos, Bio-Med Pvt. Limited, Chongqing Zhifei Biological Products Co., Ltd., GlaxoSmithKline Plc, Hualan Biological Engineering Inc., Incepta Pharmaceuticals Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd, and Walvax Biotechnology Co., Ltd. are provided in this report.

Key Benefits For Stakeholders

  • The meningococcal vaccine market share and analysis is based on a comprehensive analysis of key developments in the industry.

  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the global market.

  • The study provides an in-depth analysis of the meningococcal vaccine market trends to elucidate the imminent investment pockets.

  • The global meningococcal vaccine market trends are studied from 2018 to 2026.

  • Information about key drivers, restrains, and opportunities and their impact analysis on the meningococcal vaccine market size is provided.

  • Porter’s five forces analysis illustrates the potency of buyers and suppliers operating in the industry.

  • The quantitative analysis of the global meningococcal vaccine market from 2019 to 2026 is provided to determine the market potential.

Key Market Segments

By Vaccine Serotype

  • MenACWY
  • MenB & Manic
  • MenC
  • MenA
  • MenAC

By Vaccine Type

  • Conjugate
  • Polysaccharide
  • Subcapsular

By End User

  • Pediatric
  • Adult
  • Travelers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • the Netherlands
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle-East
    • Africa
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study

2.1.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter's five forces analysis

3.3.1.Bargaining power of buyers
3.3.2.Bargaining power of suppliers
3.3.3.Thereat of new entrants
3.3.4.Threat of substitutes
3.3.5.Intensity of competitive rivalry
3.3.6.Market share analysis, 2018

3.4.Market dynamics

3.4.1.Drivers

3.4.1.1.Increase in outbreaks of meningococcal disease
3.4.1.2.Surge in immunization programs across the globe
3.4.1.3.Increase in research and development for vaccine technology

3.4.2.Restraint

3.4.2.1.Longer timelines required for vaccine production
3.4.2.2.High costs associated with the development of vaccines

3.4.3.Opportunities

3.4.3.1.Growth opportunities in the emerging markets
3.4.3.2.Increase in healthcare spending
3.4.3.3.Increase in research and development for meningococcal vaccines

3.4.4.Impact analysis

CHAPTER 4:MENINGOCOCCAL VACCINE MARKET, BY VACCINE SEROTYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.MenACYW Vaccine

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.MenB/BC Vaccine

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.MenC Vaccine

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

4.5.MenA Vaccine

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country

4.6.MenAC Vaccine

4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country

CHAPTER 5:MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE

5.1.Overview

5.1.1.Market size and forecast

5.2.Conjugate Meningococcal Vaccines

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Polysaccharide Vaccine

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Subcapsular Vaccines

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

CHAPTER 6:MENINGOCOCCAL VACCINE MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Pediatrics

6.2.1.Market size and forecast
6.2.2.Market analysis, by country

6.3.Adults

6.3.1.Market size and forecast
6.3.2.Market analysis, by country

6.4.Traveler

6.4.1.Market size and forecast
6.4.2.Market analysis, by country

CHAPTER 7:MENINGOCOCCAL VACCINE MARKET BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country

7.2.2.1.U.S.

7.2.2.1.1.U.S. meningococcal vaccine market, by vaccine serotype
7.2.2.1.2.U.S. meningococcal vaccine market, by vaccine type
7.2.2.1.3.U.S. meningococcal vaccine market, by end user

7.2.2.2.Canada

7.2.2.2.1.Canada meningococcal vaccine market, by vaccine serotype
7.2.2.2.2.Canada meningococcal vaccine market, by vaccine type
7.2.2.2.3.Canada meningococcal vaccine market, by end user

7.2.2.3.Mexico

7.2.2.3.1.Mexico meningococcal vaccine market, by vaccine serotype
7.2.2.3.2.Mexico meningococcal vaccine market, by vaccine type
7.2.2.3.3.Mexico meningococcal vaccine market, by end user

7.2.3.North America meningococcal vaccine market, by vaccine serotype
7.2.4.North America meningococcal vaccine market, by vaccine type
7.2.5.North America meningococcal vaccine market, by end user

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country

7.3.2.1.Germany

7.3.2.1.1.Germany Meningococcal vaccines market, by Serotype
7.3.2.1.2.Germany Meningococcal vaccines market, by Vaccine type
7.3.2.1.3.Germany Meningococcal vaccines market, by end user

7.3.2.2.France

7.3.2.2.1.France Meningococcal vaccines market, by Serotype
7.3.2.2.2.France Meningococcal vaccines market, by Vaccine type
7.3.2.2.3.France Meningococcal vaccines market, by end user

7.3.2.3.UK

7.3.2.3.1.UK Meningococcal vaccines market, by Serotype
7.3.2.3.2.UK Meningococcal vaccines market, by Vaccine type
7.3.2.3.3.UK Meningococcal vaccines market, by end user

7.3.2.4.The Netherlands

7.3.2.4.1.The Netherlands Meningococcal vaccines market, by Serotype
7.3.2.4.2.The Netherlands Meningococcal vaccines market, by Vaccine type
7.3.2.4.3.The Netherlands Meningococcal vaccines market, by end user

7.3.2.5.Spain

7.3.2.5.1.Spain Meningococcal vaccines market, by Serotype
7.3.2.5.2.Spain Meningococcal vaccines market, by Vaccine type
7.3.2.5.3.Spain Meningococcal vaccines market, by end user

7.3.2.6.Rest of Europe

7.3.2.6.1.Rest of Europe Meningococcal vaccines market, by Serotype
7.3.2.6.2.Rest of Europe Meningococcal vaccines market, by Vaccine type
7.3.2.6.3.Rest of Europe Meningococcal vaccines market, by end user

7.3.3.Europe Meningococcal vaccines market, by Serotype
7.3.4.Europe Meningococcal vaccines market, by Vaccine type
7.3.5.Europe Meningococcal vaccines market, by end user

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country

7.4.2.1.China

7.4.2.1.1.China meningococcal vaccine market, by vaccine serotype
7.4.2.1.2.China meningococcal vaccine market, by vaccine type
7.4.2.1.3.China meningococcal vaccine market, by end user

7.4.2.2.Australia

7.4.2.2.1.Australia meningococcal vaccine market, by vaccine serotype
7.4.2.2.2.Australia meningococcal vaccine market, by vaccine type
7.4.2.2.3.Australia meningococcal vaccine market, by end user

7.4.2.3.Rest of Asia-Pacific

7.4.2.3.1.Rest of Asia-Pacific meningococcal vaccine market, by vaccine serotype
7.4.2.3.2.Rest of Asia-Pacific meningococcal vaccine market, by vaccine type
7.4.2.3.3.Rest of Asia-Pacific meningococcal vaccine market, by end user

7.4.3.Asia-Pacific meningococcal vaccine market, by vaccine serotype
7.4.4.Asia-Pacific meningococcal vaccine market, by vaccine type
7.4.5.Asia-Pacific meningococcal vaccine market, by end user

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country

7.5.2.1.Latin America

7.5.2.1.1.Latin America Meningococcal vaccines market, by Serotype
7.5.2.1.2.Latin America Meningococcal vaccines market, by Vaccine type
7.5.2.1.3.Latin America Meningococcal vaccines market, by end user

7.5.2.2.Middle East

7.5.2.2.1.Middle East Meningococcal vaccines market, by Serotype
7.5.2.2.2.Middle East Meningococcal vaccines market, by Vaccine type
7.5.2.2.3.Middle East Meningococcal vaccines market, by end user

7.5.2.3.Africa

7.5.2.3.1.Africa Meningococcal vaccines market, by Serotype
7.5.2.3.2.Africa meningococcal vaccines market, by vaccine type
7.5.2.3.3.Africa meningococcal vaccines market, by end user

7.5.3.LAMEA meningococcal vaccines market, by serotype
7.5.4.LAMEA meningococcal vaccines market, by vaccine type
7.5.5.LAMEA meningococcal vaccines market, by end user

CHAPTER 8:COMPANY PROFILES

8.1.Bio-Manguinhos

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio

8.2.Bio-Med Pvt. Limited

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio

8.3.Chongqing Zhifei Biological Products Co., Ltd.

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio

8.4.GlaxoSmithKline Plc

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.1.Key strategic moves and developments

8.5.Hualan Biological Engineering Inc.

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio

8.6.Incepta Pharmaceuticals Ltd.

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio

8.7.PFIZER INC.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance

8.8.SANOFI S.A.

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance

8.9.SERUM INSTITUTE OF INDIA PVT. LTD

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments

8.9.4.Product portfolio

8.10.Walvax Biotechnology Co., Ltd.

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio

LIST OF TABLES

TABLE 01.GLOBAL MENINGOCOCCAL VACCINES MARKET, BY VACCINE SEROTYPE, 2018–2026 ($MILLION)
TABLE 02.MENACWY VACCINE MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03.MENINGOCOCCAL VACCINE MARKET FOR MENB AND BC VACCINE MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04.MENINGOCOCCAL VACCINE MARKET FOR MENC MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05.MENINGOCOCCAL VACCINE MARKET FOR MENA VACCINE MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06.MENINGOCOCCAL VACCINE MARKET FOR MENAC VACCINE MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07.GLOBAL MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 08.COMPETITIVE CONJUGATE MENINGOCOCCAL VACCINES MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 09.POLYSACCHARIDE MENINGOCOCCAL VACCINES MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 10.SUBCAPSULAR MENINGOCOCCAL VACCINES MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 11.GLOBAL MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 12.MENINGOCOCCAL VACCINES MARKET FOR PEDIATRICS, BY REGION, 2018–2026 ($MILLION)
TABLE 13.MENINGOCOCCAL VACCINES MARKET FOR ADULTS, BY REGION, 2018–2026 ($MILLION)
TABLE 14.MENINGOCOCCAL VACCINES MARKET FOR TRAVELLERS, BY REGION, 2018–2026 ($MILLION)
TABLE 15.MENINGOCOCCAL VACCINE MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 16.NORTH AMERICA MENINGOCOCCAL VACCINE MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 17.U.S. MENINGOCOCCAL VACCINE MARKET, BY VACCINE SEROTYPE, 2018–2026 ($MILLION)
TABLE 18.U.S. MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 19.U.S. MENINGOCOCCAL VACCINE MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 20.CANADA MENINGOCOCCAL VACCINE MARKET, BY SEROTYPE, 2018–2026 ($MILLION)
TABLE 21.CANADA MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 22.CANADA MENINGOCOCCAL VACCINE MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 23.MEXICO MENINGOCOCCAL VACCINE MARKET, BY VACCINE SEROTYPE, 2018–2026 ($MILLION)
TABLE 24.MEXICO MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 25.MEXICO MENINGOCOCCAL VACCINE MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 26.NORTH AMERICA MENINGOCOCCAL VACCINE MARKET, BY VACCINE SEROTYPE, 2018–2026 ($MILLION)
TABLE 27.NORTH AMERICA MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 28.NORTH AMERICA MENINGOCOCCAL VACCINE MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 29.EUROPE MENINGOCOCCAL VACCINES MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 30.GERMANY MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 ($MILLION)
TABLE 31.GERMANY MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 32.GERMANY MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 33.FRANCE MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 ($MILLION)
TABLE 34.FRANCE MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 35.FRANCE MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 36.UK MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 ($MILLION)
TABLE 37.UK MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 38.UK MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 39.THE NETHERLANDS MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 ($MILLION)
TABLE 40.THE NETHERLANDS MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 41.THE NETHERLANDS MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 42.SPAIN MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 ($MILLION)
TABLE 43.SPAIN MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 44.SPAIN MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 45.REST OF EUROPE MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 ($MILLION)
TABLE 46.REST OF EUROPE MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 47.REST OF EUROPE MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 48.EUROPE MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 ($MILLION)
TABLE 49.EUROPE MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 50.EUROPE MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 51.ASIA- PACIFIC MENINGOCOCCAL VACCINE MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 52.CHINA MENINGOCOCCAL VACCINE MARKET, BY VACCINE SEROTYPE, 2018–2026 ($MILLION)
TABLE 53.CHINA MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 54.CHINA MENINGOCOCCAL VACCINE MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 55.AUSTRALIA MENINGOCOCCAL VACCINE MARKET, BY VACCINE SEROTYPE, 2018–2026 ($MILLION)
TABLE 56.AUSTRALIA MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 57.AUSTRALIA MENINGOCOCCAL VACCINE MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 58.REST OF ASIA-PACIFIC MENINGOCOCCAL VACCINE MARKET, BY VACCINE SEROTYPE, 2018–2026 ($MILLION)
TABLE 59.REST OF ASIA-PACIFIC MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 60.REST OF ASIA-PACIFIC MENINGOCOCCAL VACCINE MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 61.ASIA-PACIFIC MENINGOCOCCAL VACCINE MARKET, BY VACINE SEROTYPE, 2018–2026 ($MILLION)
TABLE 62.ASIA-PACIFIC MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 63.ASIA-PACIFIC MENINGOCOCCAL VACCINE MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 64.LAMEA MENINGOCOCCAL VACCINES MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 65.LATIN AMERICA MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 ($MILLION)
TABLE 66.LATIN AMERICA MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 67.LATIN AMERICA MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 68.MIDDLE EAST MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 ($MILLION)
TABLE 69.MIDDLE EAST MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 70.MIDDLE EAST MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 71.AFRICA MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 ($MILLION)
TABLE 72.AFRICA MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 73.AFRICA MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 74.LAMEA MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 ($MILLION)
TABLE 75.LAMEA MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 ($MILLION)
TABLE 76.LAMEA MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 77.BIO-MANGUINHOS: COMPANY SNAPSHOT
TABLE 78.BIO-MANGUINHOS: OPERATING SEGMENTS
TABLE 79.BIO-MANGUINHOS: PRODUCT PORTFOLIO
TABLE 80.BIO-MED: COMPANY SNAPSHOT
TABLE 81.BIO-MED: OPERATING SEGMENTS
TABLE 82.BIO-MED: PRODUCT PORTFOLIO
TABLE 83.ZHIFEI: COMPANY SNAPSHOT
TABLE 84.ZHIFEI: PRODUCT SEGMENTS
TABLE 85.ZHIFEI: PRODUCT PORTFOLIO
TABLE 86.GSK: COMPANY SNAPSHOT
TABLE 87.GSK: OPERATING SEGMENTS
TABLE 88.GSK: PRODUCT PORTFOLIO
TABLE 89.HUALAN BIO: COMPANY SNAPSHOT
TABLE 90.HUALAN BIO: OPERATING SEGMENTS
TABLE 91.HUALAN BIO: PRODUCT PORTFOLIO:
TABLE 92.INCEPTA: COMPANY SNAPSHOT
TABLE 93.INCEPTA: OPERATING SEGMENTS
TABLE 94.INCEPTA: PRODUCT PORTFOLIO
TABLE 95.PFIZER: COMPANY SNAPSHOT
TABLE 96.PFIZER: OPERATING SEGMENTS
TABLE 97.PFIZER: PRODUCT PORTFOLIO
TABLE 98.SANOFI: COMPANY SNAPSHOT
TABLE 99.SANOFI: OPERATING SEGMENTS
TABLE 100.SANOFI: PRODUCT PORTFOLIO:
TABLE 101.SERUM INSTITUTE.: COMPANY SNAPSHOT
TABLE 102.SERUM INSTITUTE: PRODUCT PORTFOLIO
TABLE 103.WALVAX: COMPANY SNAPSHOT
TABLE 104.WALVAX: OPERATING SEGMENTS
TABLE 105.WALVAX: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.MENINGOCOCCAL VACCINE MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS IN THE GLOBAL MENINGOCOCCAL VACCINE MARKET, 2018
FIGURE 03.MODERATE BARGAINING POWER OF BUYERS
FIGURE 04.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05.MODERATE THREAT OF NEW ENTRANTS
FIGURE 06.HIGH COMPETITIVE RIVALRY
FIGURE 07.MARKET SHARE ANALYSIS, 2018
FIGURE 08.IMPACT ANALYSIS
FIGURE 09.COMPARATIVE ANALYSIS OF MENINGOCOCCAL VACCINE MARKET, BY COUNTRY, 2018 & 2026, BY VALUE
FIGURE 10.COMPARATIVE ANALYSIS OF MENINGOCOCCAL VACCINE MARKET FOR MENB MARKET, BY COUNTRY, 2018 & 2026, BY VALUE
FIGURE 11.COMPARATIVE ANALYSIS OF MENINGOCOCCAL VACCINE MARKET FOR MENC MARKET, BY COUNTRY, 2018 & 2026, BY VALUE
FIGURE 12.COMPARATIVE ANALYSIS OF MENINGOCOCCAL VACCINE MARKET FOR MENA VACCINE MARKET, BY COUNTRY, 2018 & 2026 BY VALUE
FIGURE 13.COMPARATIVE ANALYSIS OF MENINGOCOCCAL VACCINE MARKET FOR MENAC VACCINE MARKET, BY COUNTRY, 2018 & 2026 BY VALUE
FIGURE 14.COMPARATIVE ANALYSIS OF CONJUGATE MENINGOCOCCAL VACCINES MARKET, BY COUNTRY, 2018 & 2026 (%), BY VALUE
FIGURE 15.COMPARATIVE ANALYSIS OF POLYSACCHARIDE VACCINE MARKET, BY COUNTRY, 2018 & 2026 (%), BY VALUE
FIGURE 16.COMPARATIVE ANALYSIS OF SUBCAPSULAR MENINGOCOCCAL VACCINE, BY COUNTRY, 2018 & 2026 (%), BY VALUE
FIGURE 17.COMPARATIVE ANALYSIS OF MENINGOCOCCAL VACCINES MARKET FOR PEDIATRICS, 2018 & 2026, ($MILLION)
FIGURE 18.COMPARATIVE ANALYSIS OF MENINGOCOCCAL VACCINES MARKET FOR ADULTS, 2018 & 2026, ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF MENINGOCOCCAL VACCINES MARKET FOR TRAVELLERS, 2018 & 2026, ($MILLION)
FIGURE 20.GSK: NET SALES, 2017–2018 ($MILLION)
FIGURE 21.GSK REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 22.GSK: REVENUE SHARE BY REGIONS, 2018 (%)
FIGURE 23.NET SALES, 2016–2018 ($MILLION)
FIGURE 24.PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 25.PFIZER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 26.SANOFI: NET SALES, 2016–2018 ($MILLION)
FIGURE 27.SANOFI: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 28.SANOFI: REVENUE SHARE BY REGION, 2018 (%)

 
 

Meningococcal infection is quite rare but is associated with high fatality of up to 50% if left untreated and often results in serious complications thereafter. In addition, meningococcal meningitis is also has a potential to cause large epidemics as well as endemics. There by, immunization through meningococcal vaccines is the best available defense against the disease. 

Meningococcal vaccines are expected to witness high adoption in the near future, owing to increase in number of immunization programs across the globe. In addition, the market is exhibiting high growth rate, owing to surge in awareness about use of the meningococcal vaccines. North America holds the largest share for meningococcal vaccines market. Moreover, North America and Europe are expected to offer lucrative growth opportunities to the key players. This is majorly attributed to factors such as improvement in healthcare facilities, rise in disposable income, and rapid improvement in economic conditions. However, Asia-Pacific is expected to grow at the highest rate. Meningococcal vaccine manufacturers and distributors have focused on expanding their presence in the emerging economies to strengthen their foothold in the market.
 

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, Subscription @ $699 T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
 

A. The total market value of Meningococcal market is $1935.55 million in 2018.

A. The forcast period for Meningococcal market is 2019 to 2026

A. The market value of Meningococcal market in 2020 is $2508.54 million.

A. The base year is 2018 in Meningococcal market

A. Top companies such as,GSK, Sanofi, Pfizer, Hualan, Incepta held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.

A. Vaccine serotype segment is the most influencing segment owing to surge in prevalence of meningitis disease across the globe. Hence, this leads to surge in demand for betetr management if symptoms associated with the condition.

A. The major factor that fuels the growth of the global Meningococcal market includes rise in prevalence of lifestyle disorders such as diabetes, obesity, hypertension and others. This leads to surge in demand for Meningococcal devices which contribute to the growth of the market.

A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as India with a CAGR of 14.7%. This is due to improvement in health awareness, development in healthcare infrastructure, and rise in number of hospitals & diagnostic centers equipped with advanced medical facilities.

A. contagious infection of the membranes that surround the brain and spinal cord caused by Neisseria meningitides

A. Meningococcal vaccine used to cure the diseases caused by microorganisms such as Neisseria meningitides

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Meningococcal Vaccine Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $0.00
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library. Subscription @ $699 T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts